Product Information

TRI-LO-SPRINTEC TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.1106 per EA under NDC 00093214062. Its NADAC has been published 557 times since Mar 23, 2016.

FDA first approved this application on Jun 29, 2009. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

TRI-LO-SPRINTEC TABLET

Norgestimate and Ethinyl Estradiol
$0.1106per EA

NDC

00093214062

Classification

Generic

Dosage Form

KIT

Effective Date

11/18/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA076784

FDA Approved

6/29/2009

TE Code

AB

On Market Since

12/30/2015

Price Statistics

The NADAC for TRI-LO-SPRINTEC TABLET has been published 557 times since Mar 23, 2016, and over the history we have for it it has declined 90.7%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1106 per EA
All-time high$1.1840 (Apr 13, 2016)
All-time low$0.0903 (Nov 20, 2024)
52-week high$0.1148
52-week low$0.1046
Median price$0.1709
Average price$0.2418
Largest weekly change-60.5% (Jan 18, 2017)
Weeks tracked557
Tracking sinceMar 23, 2016

Price History

1W

+2.0%

1M

+2.3%

3M

+2.1%

6M

+3.1%

1Y

-1.1%

3Y

-17.6%

5Y

-31.9%

All

-90.7%

Generic Alternatives

The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 3% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Related Drugs

Same classification

No related drugs found.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of TRI-LO-SPRINTEC TABLET?

The current National Average Drug Acquisition Cost (NADAC) for TRI-LO-SPRINTEC TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.1106 per EA (NDC 00093214062), effective Nov 18, 2026.

How has the price of TRI-LO-SPRINTEC TABLET changed over time?

Over the history we have for it, the NADAC for TRI-LO-SPRINTEC TABLET has declined 90.7%. It has been tracked across 557 weekly CMS publications since Mar 23, 2016.

What are the highest and lowest recorded NADAC prices for TRI-LO-SPRINTEC TABLET?

Since Mar 23, 2016, the NADAC for TRI-LO-SPRINTEC TABLET has ranged from a low of $0.0903 (Nov 20, 2024) to a high of $1.1840 (Apr 13, 2016), with a median of $0.1709 per EA.

Are there cheaper alternatives to TRI-LO-SPRINTEC TABLET?

Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NORG-ETHIN ESTRA 0.25-0.035 MG, is $0.1067 per EA — about 3% below TRI-LO-SPRINTEC TABLET.

Who manufactures TRI-LO-SPRINTEC TABLET?

TRI-LO-SPRINTEC TABLET (NDC 00093214062) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.